Large-scale analyses of CAV1 and CAV2 suggest their expression is higher in post-mortem ALS brain tissue and affects survival

Author:

Adey Brett N.,Cooper-Knock Johnathan,Al Khleifat Ahmad,Fogh Isabella,van Damme Philip,Corcia Philippe,Couratier Philippe,Hardiman Orla,McLaughlin Russell,Gotkine Marc,Drory Vivian,Silani Vincenzo,Ticozzi Nicola,Veldink Jan H.,van den Berg Leonard H.,de Carvalho Mamede,Pinto Susana,Mora Pardina Jesus S.,Povedano Panades Mónica,Andersen Peter M.,Weber Markus,Başak Nazli A.,Shaw Christopher E.,Shaw Pamela J.,Morrison Karen E.,Landers John E.,Glass Jonathan D.,Vourc’h Patrick,Dobson Richard J. B.,Breen Gerome,Al-Chalabi Ammar,Jones Ashley R.,Iacoangeli Alfredo

Abstract

Introduction: Caveolin-1 and Caveolin-2 (CAV1 and CAV2) are proteins associated with intercellular neurotrophic signalling. There is converging evidence that CAV1 and CAV2 (CAV1/2) genes have a role in amyotrophic lateral sclerosis (ALS). Disease-associated variants have been identified within CAV1/2 enhancers, which reduce gene expression and lead to disruption of membrane lipid rafts.Methods: Using large ALS whole-genome sequencing and post-mortem RNA sequencing datasets (5,987 and 365 tissue samples, respectively), and iPSC-derived motor neurons from 55 individuals, we investigated the role of CAV1/2 expression and enhancer variants in the ALS phenotype.Results: We report a differential expression analysis between ALS cases and controls for CAV1 and CAV2 genes across various post-mortem brain tissues and three independent datasets. CAV1 and CAV2 expression was consistently higher in ALS patients compared to controls, with significant results across the primary motor cortex, lateral motor cortex, and cerebellum. We also identify increased survival among carriers of CAV1/2 enhancer mutations compared to non-carriers within Project MinE and slower progression as measured by the ALSFRS. Carriers showed a median increase in survival of 345 days.Discussion: These results add to an increasing body of evidence linking CAV1 and CAV2 genes to ALS. We propose that carriers of CAV1/2 enhancer mutations may be conceptualised as an ALS subtype who present a less severe ALS phenotype with a longer survival duration and slower progression. Upregulation of CAV1/2 genes in ALS cases may indicate a causal pathway or a compensatory mechanism. Given prior research supporting the beneficial role of CAV1/2 expression in ALS patients, we consider a compensatory mechanism to better fit the available evidence, although further investigation into the biological pathways associated with CAV1/2 is needed to support this conclusion.

Funder

King's College London

Publisher

Frontiers Media SA

Subject

Cellular and Molecular Neuroscience

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Mutations in the tail and rod domains of the neurofilament heavy‐chain gene increase the risk of ALS;Annals of Clinical and Translational Neurology;2024-05-22

2. Non-coding genome contribution to ALS;International Review of Neurobiology;2024

3. Early Alterations in Structural and Functional Properties in the Neuromuscular Junctions of Mutant FUS Mice;International Journal of Molecular Sciences;2023-05-19

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3